Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Aerie Pharmaceuticals Stock Forecast NASDAQ:AERI
Price Target and Analyst Ratings
Historical Ratings
| Date | Upside / Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 2022-05-09 | 190.7% | HC Wainwright & Co. | $25.00 $20.00 | Maintains | Buy |
| 2022-02-25 | 103.49% | Needham | $22.00 $14.00 | Maintains | Buy |
| 2021-11-05 | 219.77% | Needham | $24.00 $22.00 | Maintains | Buy |
| 2021-08-05 | 248.84% | Needham | $26.00 $24.00 | Maintains | Buy |
| 2020-11-09 | 321.51% | HC Wainwright & Co. | $31.00 $29.00 | Maintains | Buy |
| 2020-10-19 | 30.81% | B of A Securities | $9.00 | Downgrades | Neutral Underperform |
| 2020-09-08 | 190.7% | Guggenheim | $20.00 | Initiates Coverage On | Buy |
| 2020-08-10 | 365.12% | Citigroup | $38.00 $32.00 | Maintains | Buy |
| 2020-08-07 | 277.91% | Needham | $32.00 $26.00 | Maintains | Buy |
| 2020-06-01 | 248.84% | Oppenheimer | $22.00 $24.00 | Maintains | Outperform |
| 2020-05-07 | 321.51% | Mizuho | $34.00 $29.00 | Maintains | Buy |
| 2020-05-07 | 219.77% | SunTrust Robinson Humphrey | $26.00 $22.00 | Maintains | Buy |
| 2020-05-07 | 350.58% | HC Wainwright & Co. | $37.00 $31.00 | Maintains | Buy |
| 2020-04-30 | 452.33% | Needham | $40.00 $38.00 | Maintains | Buy |
| 2020-04-13 | 423.26% | Mizuho | $54.00 $36.00 | Maintains | Buy |
| 2020-04-13 | 277.91% | Oppenheimer | $28.00 $26.00 | Maintains | Outperform |
| 2020-04-01 | 481.4% | Stifel | $45.00 $40.00 | Maintains | Buy |
| 2020-03-23 | 147.09% | B of A Securities | $26.00 $17.00 | Maintains | Neutral |
| 2020-02-21 | 437.79% | HC Wainwright & Co. | $41.00 $37.00 | Maintains | Buy |
| 2019-11-07 | 597.67% | Piper Sandler | $53.00 $48.00 | Maintains | Overweight |
| 2019-11-07 | 554.07% | Stifel | $77.00 $45.00 | Maintains | Buy |
| 2019-11-07 | 336.05% | Cantor Fitzgerald | $62.00 $30.00 | Maintains | Overweight |
| 2019-08-08 | 655.81% | JMP Securities | $58.00 $52.00 | Reiterates | Market Outperform |
| 2019-08-08 | 801.16% | Cantor Fitzgerald | $85.00 $62.00 | Reiterates | Overweight |
AERI Stock Trend
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.
Given the current short-term trend, the stock is expected to fall -6.79% during the next 3 months and, with a 90% probability hold a price between $5.34 and $8.78 at the end of this 3-month period.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2022-05-18 | $5.72 | $7.57 | $9.41 |
| 2022-05-19 | $5.71 | $7.55 | $9.40 |
| 2022-05-20 | $5.70 | $7.54 | $9.39 |
| 2022-05-23 | $5.69 | $7.53 | $9.38 |
| 2022-05-24 | $5.68 | $7.52 | $9.37 |
| 2022-05-25 | $5.66 | $7.51 | $9.35 |
| 2022-05-26 | $5.65 | $7.50 | $9.34 |
| 2022-05-27 | $5.64 | $7.49 | $9.33 |
| 2022-05-31 | $5.63 | $7.47 | $9.32 |
| 2022-06-01 | $5.62 | $7.46 | $9.31 |
| 2022-06-02 | $5.61 | $7.45 | $9.30 |
| 2022-06-03 | $5.60 | $7.44 | $9.29 |
| 2022-06-06 | $5.58 | $7.43 | $9.27 |
| 2022-06-07 | $5.57 | $7.42 | $9.26 |
| 2022-06-08 | $5.56 | $7.41 | $9.25 |
| 2022-06-09 | $5.55 | $7.39 | $9.24 |
| 2022-06-10 | $5.54 | $7.38 | $9.23 |
| 2022-06-13 | $5.53 | $7.37 | $9.22 |
| 2022-06-14 | $5.52 | $7.36 | $9.21 |
| 2022-06-15 | $5.50 | $7.35 | $9.19 |
| 2022-06-16 | $5.49 | $7.34 | $9.18 |
| 2022-06-17 | $5.48 | $7.33 | $9.17 |
| 2022-06-21 | $5.47 | $7.31 | $9.16 |
| 2022-06-22 | $5.46 | $7.30 | $9.15 |
| 2022-06-23 | $5.45 | $7.29 | $9.14 |
| 2022-06-24 | $5.44 | $7.28 | $9.13 |
| 2022-06-27 | $5.42 | $7.27 | $9.11 |
| 2022-06-28 | $5.41 | $7.26 | $9.10 |
| 2022-06-29 | $5.40 | $7.25 | $9.09 |
| 2022-06-30 | $5.39 | $7.23 | $9.08 |
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its product candidates include Rhopressa, a once-daily eye drop, which has completed Phase III registration trials for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Roclatan, a once-dai... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 108 000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
